Semax Research Guide: ACTH 4-10 Fragment & Neurotrophic Biology

Last Updated: April 14, 2026

Semax is a synthetic heptapeptide derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH), extended at the C-terminus with the stabilizing tripeptide Pro-Gly-Pro. Its amino acid sequence—Met-Glu-His-Phe-Pro-Gly-Pro—retains the cognitive and behaviorally active core of ACTH 4-10 while eliminating the corticotropic domain responsible for adrenal axis activation. This deliberate structural choice, made by Russian investigators at the Institute of Molecular Genetics of the Russian Academy of Sciences, yields a research peptide that engages neurotrophic and cognitive-enhancement pathways without stimulating cortisol release. Preclinical research indicates Semax modulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, influences dopaminergic and serotonergic turnover, and produces neuroprotective signatures in rodent models of ischemic injury. This semax research guide synthesizes the peptide’s structural biology, published mechanism hypotheses, foundational literature, and standard laboratory handling protocols for investigators working with reference material in experimental settings.

What Is Semax and Why Is the ACTH 4-10 Fragment Significant?

Semax is constructed around the 4-10 segment of adrenocorticotropic hormone, a decades-old research target identified by investigators examining which portions of the ACTH molecule contribute to its reported effects on attention, memory, and motivation in animal models. The ACTH 4-10 fragment (Met-Glu-His-Phe-Arg-Trp-Gly) was isolated as the region responsible for these behavioral signatures, distinct from the adrenal-activating C-terminal portions of the full hormone. Semax takes the first four residues of ACTH 4-10 (Met-Glu-His-Phe) and appends Pro-Gly-Pro, yielding a stabilized heptapeptide that retains the cognitive-associated core while gaining substantial resistance to peptidase degradation. Preclinical research indicates this strategy produces a molecule with measurable neurological activity but without the corticotropic effects of the parent hormone, making it a useful tool for investigators studying the non-endocrine actions of ACTH-derived sequences.

What Does the Pro-Gly-Pro Modification Accomplish?

The Pro-Gly-Pro C-terminal extension is a structural strategy shared across multiple Russian research peptides, including Semax and Selank. Proline residues disrupt the typical peptide backbone geometry required for carboxypeptidase recognition, and the triple-proline-glycine-proline arrangement sterically shields the biologically active N-terminal core from enzymatic cleavage. Published studies suggest this extension increases measurable peptide half-life in plasma by roughly an order of magnitude compared with unmodified ACTH 4-10 fragments, transforming an otherwise rapidly degraded motif into a tractable research compound. Preclinical research indicates the stabilizing tail does not itself contribute to the behavioral or neurotrophic signature—Met-Glu-His-Phe carries that activity—but is essential for the molecule’s laboratory utility. This modular “active core plus stabilizing tail” architecture is a recurring theme in the nootropic peptides research literature.

How Does Semax Modulate BDNF and NGF?

Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are neurotrophins central to neuronal survival, synaptic plasticity, and learning-associated circuit remodeling. Preclinical research indicates Semax administration upregulates both BDNF and NGF expression in hippocampal and cortical tissue in rodent models, with increases observable within hours of administration and persisting through the experimental window. Published studies suggest this neurotrophin modulation underlies much of Semax’s reported cognitive-associated activity, including preserved or enhanced performance on maze, avoidance, and recognition tasks in animal research. Investigators have also reported downstream effects on tropomyosin receptor kinase (TrkA and TrkB) signaling consistent with activated neurotrophin receptor pathways. See Dolotov et al. (PMID 12027050) for foundational characterization of Semax’s interaction with the BDNF system in rodent brain tissue.

Why Does Semax Not Activate the Adrenal Axis?

Full-length adrenocorticotropic hormone activates the adrenal cortex by binding melanocortin-2 receptors and stimulating cortisol release. The receptor-binding determinants for this corticotropic activity reside in portions of ACTH outside the 4-10 fragment—specifically the N-terminal residues and C-terminal extensions that together form the MC2R recognition surface. Semax, built around the 4-10 core (truncated to residues 4-7 plus Pro-Gly-Pro), lacks these corticotropic determinants entirely. Preclinical research indicates Semax administration does not elevate plasma cortisol or corticosterone in rodent models, distinguishing it sharply from full ACTH preparations. This decoupling of cognitive-associated activity from endocrine activation is a central feature of the molecule’s research profile and the reason investigators studying ACTH-derived behavioral signatures can use Semax as a selective probe for non-endocrine pathways without confounding stress-axis readouts.

What Cognitive-Enhancement Research Exists for Semax?

Preclinical research indicates Semax produces measurable effects across standard rodent cognitive paradigms, including Morris water maze, passive avoidance, novel object recognition, and attention-associated tasks. Published studies suggest animals receiving Semax under research protocols show preserved or improved performance on acquisition and retention metrics compared with vehicle controls, with effect sizes varying by paradigm and model. The cognitive-associated signature is generally interpreted as downstream of the peptide’s neurotrophic activity—BDNF and NGF upregulation supporting synaptic plasticity—combined with modulation of dopaminergic and serotonergic turnover in frontal and hippocampal regions. For broader comparative context, the Selank vs Semax reference examines how Semax’s cognitive-forward profile contrasts with Selank’s anxiolytic-forward signature, despite their shared Russian research lineage and Pro-Gly-Pro architecture.

What Do Stroke Model Studies Show?

A substantial portion of the Semax preclinical literature examines neuroprotective signatures in rodent models of cerebral ischemia. Published studies suggest Semax administration around experimental ischemic events reduces infarct volume, preserves neuronal density in peri-infarct tissue, and improves performance on post-ischemic behavioral recovery tasks compared with vehicle controls. Preclinical research indicates mechanisms underlying these findings include upregulation of neurotrophin expression, reduction of oxidative stress markers, and modulation of inflammatory cytokine profiles in affected tissue. Medvedeva et al. (PMID 23912820) provides characterization of gene expression changes in rodent brain tissue following Semax administration in ischemia-related protocols. Investigators studying neuroprotection, recovery trajectories, and neurotrophin-mediated tissue preservation in stroke models have cited Semax as a useful experimental tool in this domain.

What Attention and Motivation Paradigms Use Semax?

Preclinical research indicates Semax produces measurable effects in attention-associated and motivation-related behavioral paradigms, drawing on the original identification of ACTH 4-10 as a fragment linked to these cognitive domains in classical peptide research. Investigators have reported signatures in sustained attention tasks, discriminative learning paradigms, and reward-related operant procedures in rodent models, with effect patterns generally interpreted as consistent with monoaminergic modulation of frontal-striatal circuitry combined with neurotrophin-supported plasticity. Published studies suggest these attention and motivation readouts complement the more extensively characterized memory and neuroprotective signatures, providing a multidimensional behavioral profile that supports Semax’s use as a research tool in studies of executive function circuitry. The breadth of this behavioral signature is one reason Semax appears in review literature addressing ACTH-derived peptides as probes for non-endocrine cognitive and motivational pathways.

What Is Semax’s Russian Regulatory and Research History?

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences with substantial pharmacological characterization carried out in collaboration with affiliated research groups. The molecule received regulatory approval in the Russian Federation for specific clinical indications following domestic review, and it remains part of the Russian medical formulary under national regulation. Outside Russia, Semax does not hold marketing authorization in major regulatory jurisdictions and is appropriately characterized as a research-grade compound for laboratory use by investigators working outside the Russian regulatory context. The bulk of the foundational preclinical and mechanism literature originates from Russian groups and is available through PubMed indexing, providing the basis for mechanism hypotheses and experimental design strategies that non-Russian investigators use when designing laboratory protocols with Semax as a reference compound for cognitive, neurotrophic, or neuroprotective research questions.

What Monoamine Turnover Effects Have Been Characterized?

Beyond neurotrophin modulation, preclinical research indicates Semax influences dopaminergic and serotonergic turnover in frontal cortex, striatum, and hippocampus in rodent models. Published studies using microdialysis and post-mortem neurochemistry have reported shifts in monoamine metabolite ratios following Semax administration, consistent with modulation of synthesis, release, or reuptake at multiple transmitter systems. Investigators have proposed that these monoaminergic effects contribute to the peptide’s cognitive-associated and attention-related signatures observed in behavioral paradigms, complementing the slower-onset neurotrophic mechanisms mediated by BDNF and NGF upregulation. This combination of rapid neurochemical modulation and sustained neurotrophic support is cited in the Russian research literature as a distinguishing feature of Semax compared with single-mechanism reference compounds, and positions the molecule as a multi-scale experimental tool for investigators studying the interplay between neurotransmitter dynamics and neurotrophin-mediated circuit remodeling in animal research.

What Gene Expression Signatures Follow Semax Administration?

Transcriptomic and targeted gene expression studies form a substantial portion of the Semax research literature, with investigators using microarray and quantitative PCR approaches to map changes in brain tissue following administration in rodent protocols. Published studies suggest Semax produces coordinated shifts in the expression of neurotrophin genes (BDNF, NGF), their receptors (TrkA, TrkB), and downstream effectors involved in synaptic plasticity, neuronal survival, and anti-apoptotic signaling. Medvedeva et al. (PMID 23912820) describes gene expression changes associated with ischemic research protocols and illustrates the breadth of transcriptional modulation observed. Preclinical research indicates these gene expression signatures are time-dependent and region-specific, providing investigators with a molecular readout that complements behavioral and histological endpoints in laboratory studies of Semax mechanism and neuroprotective profile.

How Is Semax Reconstituted and Stored for Research Protocols?

Semax is supplied as a lyophilized white powder and should be stored at −20 °C in its sealed vial until reconstitution for laboratory use. Standard research protocols reconstitute lyophilized Semax with bacteriostatic water or sterile water depending on experimental requirements, with diluent introduced slowly along the vial wall to minimize mechanical stress on the peptide. Gentle swirling—never vigorous shaking—is used to dissolve the powder. Reconstituted solutions are typically stored at 2–8 °C and used within published stability windows, with freeze-thaw cycles minimized. Concentration is calculated from the stated vial mass and diluent volume, and aliquoting into single-use fractions prior to freezing is common for extended protocols. All handling is conducted under laboratory conditions appropriate for research reference material and consistent with the research-only purpose of the compound, with written reconstitution and storage logs maintained to support reproducibility.

Frequently Asked Questions

What is the structural relationship between Semax and ACTH?

Adrenocorticotropic hormone is a 39-residue peptide hormone whose 4-10 fragment (Met-Glu-His-Phe-Arg-Trp-Gly) was identified by researchers as the region responsible for non-endocrine behavioral effects. Semax takes the first four residues of this fragment (Met-Glu-His-Phe) and extends the sequence with the stabilizing tripeptide Pro-Gly-Pro, yielding the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. Preclinical research indicates this structure retains the cognitive-associated core of ACTH 4-10 while the C-terminal Pro-Gly-Pro extension confers peptidase resistance and eliminates the corticotropic receptor-binding surface required for adrenal activation. Published studies suggest this makes Semax a selective tool for probing the non-endocrine, neurotrophic, and cognitive-associated activities originally identified in the ACTH 4-10 segment without the confounding stress-axis effects of full-length ACTH.

How does Semax differ from Selank in research applications?

Semax and Selank share a Russian research lineage, a Pro-Gly-Pro C-terminal stabilizing tail, and heptapeptide architecture, but their active cores and research signatures diverge. Selank is built on the tuftsin tetrapeptide (Thr-Lys-Pro-Arg) and exhibits anxiolytic-like and immunomodulatory activity in preclinical models. Semax is built on the ACTH 4-10-derived Met-Glu-His-Phe core and exhibits cognitive-associated and neurotrophic activity with BDNF/NGF modulation. Preclinical research indicates Selank is typically selected for anxiety-associated research questions, while Semax is selected for cognitive, neurotrophic, and neuroprotective research questions. See the Selank vs Semax comparison for a detailed side-by-side of sequences, mechanism hypotheses, and representative published studies to inform protocol selection.

What is the mechanism linking Semax to BDNF and NGF?

Published studies suggest Semax administration upregulates transcription of BDNF and NGF genes in hippocampal and cortical tissue in rodent models, with increases observable within hours and sustained through experimental windows. Preclinical research indicates downstream activation of tropomyosin receptor kinase signaling (TrkA for NGF, TrkB for BDNF), consistent with neurotrophin receptor engagement. Investigators have proposed that the cognitive-associated signatures observed in maze, avoidance, and recognition paradigms reflect this neurotrophin-mediated support for synaptic plasticity and neuronal survival. Dolotov et al. (PMID 12027050) provides foundational characterization, and later publications extend the mechanism to downstream signaling and gene expression cascades relevant to learning-associated circuit remodeling in animal research.

Does Semax affect cortisol or the HPA axis?

Preclinical research indicates Semax does not activate the hypothalamic-pituitary-adrenal axis or elevate plasma cortisol/corticosterone in rodent models, because the molecule lacks the melanocortin-2 receptor recognition surface present in full-length ACTH. The Met-Glu-His-Phe core retained by Semax carries cognitive-associated and neurotrophic activity but not the corticotropic determinants that drive adrenal cortisol release. Published studies documenting stress-axis readouts following Semax administration consistently report values indistinguishable from vehicle controls. This decoupling is a central reason investigators select Semax as a probe for the non-endocrine actions of ACTH-derived sequences—it allows experimental designs that examine cognitive or neurotrophic signatures without confounding endocrine activation that would complicate interpretation of behavioral or gene expression readouts in animal research protocols.

What published studies form the foundation of Semax research?

The foundational preclinical and mechanism characterization of Semax is concentrated in publications from Russian research groups affiliated with the Institute of Molecular Genetics and partner institutions. Key references include Dolotov et al. (PMID 12027050), which characterizes Semax interaction with the BDNF system in rat brain, and Medvedeva et al. (PMID 23912820), which describes gene expression changes in rodent brain tissue following Semax administration in ischemia-associated research protocols. Additional PubMed-indexed publications document effects on monoamine turnover, neuroprotection in stroke models, and cognitive-associated signatures in behavioral paradigms. Investigators designing Semax-based research protocols typically combine these foundational Russian sources with later international publications to establish mechanism hypotheses and appropriate experimental controls.

What are standard reconstitution practices for Semax?

Standard research protocols reconstitute lyophilized Semax with bacteriostatic water or sterile water for laboratory use, with diluent volume calculated from the stated vial mass and desired working concentration. The diluent is introduced slowly along the vial wall to minimize mechanical stress on the peptide, and the vial is swirled gently—never shaken vigorously—until the powder fully dissolves. Reconstituted solutions are stored at 2–8 °C within published stability windows, and freeze-thaw cycles are minimized. For extended-use protocols, aliquoting into single-use fractions prior to freezing is common. The lyophilized vial itself is stored at −20 °C until reconstitution. All handling conforms to laboratory conditions appropriate for research reference material, and investigators should maintain written reconstitution and storage logs to support reproducibility across experimental replicates and protocol iterations.

Where can investigators source Semax for research?

Peptideware supplies Semax 10mg as lyophilized reference material for laboratory and research purposes only. Each vial is characterized for identity and purity and is packaged under conditions consistent with published storage protocols. Investigators working on comparative nootropic peptide research may also find the nootropic peptides guide and the Selank vs Semax comparison useful references for protocol design and literature triangulation. All products are intended for laboratory and research purposes only, are not for human or animal consumption, and are supplied with documentation appropriate for research-grade material used in preclinical and laboratory-based experimental work.

---

Research Disclaimer: All products are intended for laboratory and research purposes only. Not for human or animal consumption. These statements have not been evaluated by the FDA. Content on this page summarizes published preclinical literature and is provided for educational reference to investigators working with research-grade material.